Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported to be lost by the shareholder as per the attachment. The shareholder has requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the shareholder on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record.
10-03-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Early Redemption Of 4.875% Senior Notes Due 2021 By Jubilant Pharma Limited, Wholly-Owned Subsidiary Of The Company (A Company Incorporated Under The Laws Of Singapore)

 We refer to our intimation dated February 3, 2021 regarding the proposed early redemption of principal amount of US$100,000,000 out of US$300,000,000 4.875% Senior Notes due 2021 (the 'Notes') issued by our material wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore) ('JPL'). Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that JPL has on March 5, 2021 redeemed the principal amount of US$100,000,000 out of US$300,000,000 Notes at a redemption price of 101.21875% together with the accrued interest till date. JPL had made the first early redemption of US$100,000,000 in November 2019 and the second early redemption of US$100,000,000 on January 29, 2021. After the redemption of US$100,000,000 on March 5, 2021, the Notes have been paid in full and no amount remains outstanding under the Notes.
05-03-2021
Bigul

Jubilant Pharmova Ltd - 530019 - Submission Of Trust Deed

 Pursuant to Regulation 3(3) of the SEBI (Share Based Employee Benefits) Regulations, 2014, we enclose the executed Trust Deed. This is for your information and record.
12-02-2021
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to the provisions of Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has issued duplicate share certificate as per the attachment. This is for your information and record.
10-02-2021
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation of our letter dated February 5, 2021, we enclose copies of the Unaudited Consolidated Financial Results for the quarter ended December 31, 2020 published on February 6, 2021 in MINT (English) and HINDUSTAN (Hindi).
06-02-2021
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Composite Scheme of Arrangement - Restructuring of the Board of Directors of the Company
06-02-2021

Earnings Call for Q3FY21 of Jubilant Pharmova (Jubilant Life Sciences)

 Conference Call with Jubilant Pharmova Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.
05-02-2021
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Financial Results (Standalone And Consolidated) For The Quarter Ended December 31, 2020

 In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2020 were approved by the Board of Directors of the Company at its meeting held today at 1.00 p.m. and concluded at 2.50 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2020; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records.
05-02-2021
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Early Redemption Of 4.875% Senior Notes Due 2021 By Jubilant Pharma Limited, Wholly-Owned Subsidiary Of The Company (A Company Incorporated Under The Laws Of Singapore)

 We wish to inform you that our material wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore) ('JPL') has given notice to the holders of its US$300,000,000 4.875% Senior Notes due 2021 (the 'Notes') that it has elected to exercise its option to redeem US$100,000,000 in aggregate principal amount of the Notes on March 5, 2021 (the 'Redemption Date') pursuant to the terms of the indenture dated as of October 6, 2016 (the 'Indenture') between JPL and The Bank of New York Mellon, London Branch as trustee, governing the Notes. JPL had made the first early redemption of US$100,000,000 in November 2019 and the second early redemption of US$100,000,000 on January 29, 2021, and following the proposed redemption of US$100,000,000 on March 5, 2021, the Notes will be paid in full and no amount will remain outstanding under the Notes.
03-02-2021
Bigul

JUBILANT LIFE SCIENCES LIMITED - 530019 - Effective Date Of Demerger And Change Of Name Of The Company

 Effective Date of Demerger and Change of Name of the Company
01-02-2021
Next Page
Close

Let's Open Free Demat Account